Amphastar Pharmaceuticals director Petersen sells $27,986 in stock

Published 07/03/2025, 22:04
Amphastar Pharmaceuticals director Petersen sells $27,986 in stock

Petersen Floyd F., a director at Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), executed a sale of 1,000 shares of the company’s common stock on March 6, 2025. The shares were sold at a weighted average price of $27.9863, resulting in a total transaction value of $27,986. The transaction occurs as the stock trades near its 52-week low of $26.98, despite the company’s strong financial health score of "GREAT" according to InvestingPro analysis. This transaction was conducted under a Rule 10b5-1 trading plan, which was adopted by Petersen on November 26, 2024. Following this sale, Petersen retains ownership of 74,409 shares in Amphastar Pharmaceuticals.

The shares were sold in multiple transactions, with prices ranging from $27.66 to $28.295. The company is headquartered in Rancho Cucamonga, California, and specializes in pharmaceutical preparations.

In other recent news, Amphastar Pharmaceuticals reported its fourth-quarter 2024 earnings, which fell short of analyst expectations. The company announced an EPS of $0.92, missing the forecast of $0.97, and revenue of $186.5 million, which was below the anticipated $192.69 million. Amphastar’s annual revenue reached $732 million, marking a 14% increase year-over-year. Despite the revenue growth, the company experienced a decline in gross margins, which dropped to 46.5% from 54% the previous year. Amphastar anticipates flat sales in 2025 but remains hopeful for a return to growth in 2026, focusing on new product launches and expanding its manufacturing capacity. The company also announced a strategic partnership with MannKind (NASDAQ:MNKD) to promote Baximi, enhancing its sales reach in the diabetes care market. In terms of competition, Amphastar faces challenges in maintaining market share for its glucagon and epinephrine products due to increased competition. The company is preparing for potential approvals of four key products in 2025, which could impact its future growth trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.